Anti‐vascular endothelial growth factor biologics are now the standard of care for wet AMD and other ocular neovascular diseases including diabetic macular edema, retinal vein occlusion, and retinopathy of prematurity (Kim & D'Amore, 2012). The gene discussed is VEGFA; the disease is wet macular degeneration.